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ABSTRACT
Background In systemic sclerosis (SSc), chronic and
uncontrolled overexpression of vascular endothelial
growth factor (VEGF) results in chaotic vessels, and
intractable ﬁngertip ulcers. Vice versa, VEGF is a potent
mediator of angiogenesis if temporally and spatially
controlled. We have addressed this therapeutic dilemma
in SSc by a novel approach using a VEGF121 variant that
covalently binds to ﬁbrin and gets released on demand
by cellular enzymatic activity. Using University of
California at Davis (UCD)-206 chickens, we tested the
hypothesis that cell-demanded release of ﬁbrin-bound
VEGF121 leads to the formation of stable blood vessels,
and clinical improvement of ischaemic lesions.
Methods Ninety-one early and late ischaemic comb
and neck skin lesions of UCD-206 chickens were treated
locally with VEGF121-ﬁbrin, ﬁbrin alone, or left
untreated. After 1 week of treatment the clinical
outcome was assessed. Angiogenesis was studied by
immunoﬂuorescence staining of vascular markers
quantitatively analysed using TissueQuest.
Results Overall, 79.3% of the lesions treated with
VEGF121-ﬁbrin showed clinical improvement, whereas
71.0% of ﬁbrin treated controls, and 93.1% of
untreated lesions deteriorated. This was accompanied by
signiﬁcantly increased growth of stable microvessels,
upregulation of the proangiogenic VEGFR-2 and its
regulator TAL-1, and increase of endogenous endothelial
VEGF expression.
Conclusions Our ﬁndings in the avian model of SSc
suggest that cell-demanded release of VEGF121 from
ﬁbrin matrix induces controlled angiogenesis by
differential regulation of VEGFR-1 and VEGFR-2
expression, shifting the balance towards the
proangiogenic VEGFR-2. The study shows the potential
of covalently conjugated VEGF-ﬁbrin matrices for the
therapy of ischaemic lesions such as ﬁngertip ulcers.
INTRODUCTION
Systemic sclerosis (SSc, scleroderma), a devastating
autoimmune connective tissue disease affecting the
skin and viscera, is characterised by microangiopa-
thy, immunological abnormalities and ﬁbrosis.1
Although great progress has been made in unscram-
bling the complex pathogenic interactions between
the immune system, the vasculature and ﬁbrotic
processes, the ultimate aetiology still remains
unclear.2 However, apoptosis of endothelial cells
(ECs) is considered to be a primary event in the
pathogenesis of SSc that precedes inﬂammation and
ﬁbrosis.3
The search for the ultimate aetiology as well as
the evaluation of new therapeutic approaches
requires appropriate animal models. The University
of California at Davis (UCD) chicken lines 200 and
206 are the only animal model displaying all hall-
marks of SSc, that is, microvascular damage, severe
perivascular mononuclear cell inﬁltration, and
ﬁbrosis of skin and viscera, circulating antinuclear
antibodies, and anti-EC antibodies.4
Vascular alterations in human and avian SSc pre-
dominantly affect the microvasculature with intimal
proliferation, occlusion of blood vessel and capil-
lary necrosis, leading to a decreased blood ﬂow, a
state of chronic ischaemia and clinical manifesta-
tions such as ﬁngertip ulcers and comb lesions.5 6
Tissue hypoxia normally induces neoangiogenesis,
but in SSc vascular repair and angiogenesis seem to
be strongly disturbed.7–9 One of the key molecules
in the induction of angiogenesis is vascular endo-
thelial growth factor (VEGF). It is involved in
several steps of angiogenesis including migration,
proliferation and survival of ECs.10 In patients with
SSc, VEGF expression is upregulated, but seems to
be uncontrolled and chronic.11–14 Sufﬁcient angio-
genesis depends on the tight regulation of VEGF
expression.15 Prolonged exposure to VEGF results
in the formation of a chaotic capillary network
with irregularly shaped, dilated capillaries, a
morphology similar to that seen in SSc.16 17 Thus,
the chronic VEGF overexpression found in SSc
might paradoxically lead to a disturbed vessel
morphology rather than to promote the formation
of new functional and stable vessels. Recently,
increased serum levels of the antiangiogenic
VEGF165b isoform have been reported in patients
with SSc, which could at least partly explain the
lack of sufﬁcient angiogenesis despite strongly ele-
vated VEGF levels.18 However, very high levels of
VEGF are associated with the absence of ﬁngertip
ulcers.11 19 This suggests that the concentrations of
proangiogenic VEGF isoforms have to exceed a
certain threshold level to overcome the inhibitory
effects of antiangiogenic factors, and that a further
increase of VEGF might have beneﬁcial effects in
the prevention and therapy of ﬁngertip ulcers. Yet,
therapeutic VEGF can play either a helpful or
harmful role in tissue vascularisation, depending on
the dose and pharmacokinetics of its administra-
tion.16 20 21 Hence, uncontrolled long-term
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overexpression as in SSc or a burst release leads to chaotic
morphology of the newly formed vessels with reduced blood
ﬂow, whereas a short-time upregulation of VEGF initiates angio-
genesis, which results in the formation of stable blood vessels.22
Thus, in SSc, there is a therapeutic need for a temporally and
spatially controlled availability of proangiogenic VEGF at sites
of ischaemia (eg, ﬁngertip ulcers).
In nature, the longer VEGF isoforms are bound to extracellular
matrix (ECM) components until liberated in a tightly controlled
manner by local enzymatic activity of cells invading the matrix.23
The ECM provides a bioactive dynamic structure, which controls
EC activities by various mechanisms ranging from cell anchorage
and growth factor binding to integrin-mediated activation, and
thus is crucial for functional and sustained vascular growth.24 In
order to mimic nature, Andreas Zisch et al25 have developed a
method to covalently bind VEGF121 to a ﬁbrin matrix, in which
VEGF121 is released upon demand by enzymatic cleavage.
Grafting experiments with this ﬁbrin-bound VEGF variant
demonstrated controlled growth of morphologically normal
blood vessels.26 Based on this evidence, we hypothesised that
local administration of VEGF121-ﬁbrin and consequent cell
demanded release of VEGF from the ﬁbrin matrix should over-
come the uncontrolled VEGF expression found in SSc, and
induce sufﬁcient angiogenesis to heal and prevent ischaemic
ulcers. Here we present the therapeutic efﬁcacy of this novel
approach in the spontaneous avian model of SSc.
MATERIALS AND METHODS
Animals and study design
UCD-206 chickens were bred and maintained at the Central
Laboratory Animal Facilities of the Medical University of
Innsbruck. Animal breeding, housing, treatment and collection
of tissue samples were carried out in accordance with the
Animal Experiment Directive of the European Union (Directive
2010/63 EU) and the Austrian law on the protection of animals
used for scientiﬁc purposes (‘Tierversuchsgesetz’ BGBL I Nr.
501/1989 idF 2005 and BGBL I Nr. 114/2012) after approval
by the Federal Ministry of Science and Research (GZ 66.011/
082-C/GT/2007, GZ 66.011/082-C/GT/2010, and GZ 66.011/
077-WF/II/3b/2014). The clinical stage of early skin lesions is
classiﬁed in the comb as C+ (erythema), C++ (erythema and
oedema), C+++ (ulceration with onset of necrosis), C++++
(comb lost due to self dubbing) in the neck skin as N+ (ery-
thema), N++ (erythema and oedema), and N+++ (ulceration
with onset of necrosis), N++++ (ﬁbrosis).3 Comb lesions
developed between 9 days and 27 days of age (mean 14.7±4.1
SD), neck lesions between 22 days and 37 days of age (mean
26.0±3.9 SD).
For the present study, lesions were treated at the stages of
C++ and C+++, neck lesions at stage N+++ either with
VEGF121 modiﬁed ﬁbrin gel, with ﬁbrin gel only, or left
untreated (comb lesions n=10 per group, neck lesions treated
with VEGF121-ﬁbrin or ﬁbrin n=11 each, untreated n=9).
Chickens were randomly assigned to receive VEGF121-ﬁbrin,
ﬁbrin or no treatment, and received a code for blinded clinical
and histological analyses.
Procedures
In order to mimic the natural binding of VEGF to ECM, we
used VEGF121 modiﬁed with the factor XIIIa substrate sequence
NQEQVSPL. This variant, α2PI1-8-VEGF121, spontaneously
cross-links to ﬁbrinogen by the transglutamination activity of
factor XIII (FXIII) during ﬁbrin polymerisation.25
VEGF121-ﬁbrin gel matrices were prepared by mixing 20 μg/mL
α2PI1-8-VEGF121 (kindly provided by A Zisch) with ﬁbrinogen
solution (Tisseel, Baxter AG, Vienna, Austria) diluted with
sterile Tris buffered saline (pH 7.2) to a ﬁnal concentration of
10 mg/mL ﬁbrinogen, and 2 U/mL FXIII (Baxter AG, Vienna,
Austria) prior to initiation of ﬁbrin gelation by addition of
2 U/mL thrombin (Tisseel, Baxter AG, Vienna, Austria). For
placebo control, α2PI1-8-VEGF121 was omitted. The mixture was
immediately applied to the lesion with the help of a small plastic
ring to keep it in place till gel was formed, which took 20–30 s.
The ring was then removed, and the gel covered with Opsite
Flexigrid (Smith & Nephew, Hull, UK) to keep it moist.
After 7 days, the dressing was removed; pictures were taken
for documentation and macroscopic analysis by comparison
with pictures taken before treatment. The animals were sacri-
ﬁced under Narkodorm anaesthesia (Pentobarbital, CP-Pharma,
D-31303 Burgdorf, Germany, 20 mg/kg intravenous) by cardiac
exsanguinisation. Combs and neck skin biopsies were shock
frozen in liquid nitrogen and stored at −196°C till further ana-
lyses. The clinical outcome was evaluated by three experts (HD,
JG and RS) independently, and in a blinded manner. The degree
of change was scored as follows: 0=no change, +1=improve-
ment, +2=strong improvement, −1=deterioration, −2=strong
deterioration.
Immunoﬂuorescence staining
Angiogenesis was studied by indirect immunoﬂuorescence (IIF)
tests on 4 μm frozen tissue sections using antibodies speciﬁc for
the EC marker von Willebrand factor (vWF), and α smooth
muscle actin (αSMA) or desmin, which are expressed by peri-
cytes (PCs) and smooth muscle cells (SMCs), and serve as
markers for stable blood vessel formation. Expression of VEGF,
VEGFR-1, VEGFR-2 and TAL-1 by ECs was also analysed by
IIF double staining with the respective antibody and anti-vWF
antibody. Nuclei were stained with DAPI. See online supplemen-
tary text for details on antibodies and staining procedure.
Microscopy and quantitative analysis
IIF staining was analysed in a blinded manner using a Nikon
Eclipse E800 ﬂuorescence microscope (Nikon, Tokyo, Japan).
For quantitative analysis digital black and white (b/w) pictures
were acquired from 10 ﬁelds of view per tissue section using a
20× objective lens (Plan Apo 20×/0.75 DICM α/0.17 WD 1.0)
with ﬁlter settings for FITC, RRX and DAPI in series ( jpeg ﬁne,
size 1280×960, source s1.3M, CCD mode).
ECs and non-ECs expressing VEGF, VEGFRs or TAL-1 were
quantiﬁed using the image analysis software TissueQuest cyt-
ometer (TQ 4.0 TissueQuest Software, TissueGnostics, Vienna,
Austria). This microscopy-based multicolour tissue cytometry
software permits multicolour analysis of single cells within
tissue sections similar to ﬂow cytometry. The principle of the
method and the algorithms used have been described in detail
elsewhere.27 In brief, the DAPI channel is the master marker for
the identiﬁcation of all events. This mask is then used in a cor-
rected form to measure staining intensity in the other channels.
Cut-off values for FITC and RRX channels were deﬁned accord-
ing to isotype controls, coexpressions were depicted in scatter-
grams of normalised grey values, and numbers of single positive
and double positive cells were calculated as cells per mm2. To dis-
criminate PCs and SMCs, parameters were chosen in order to
identify αSMA positive cells within the basal lamina and outside.
Statistical analysis
GraphPad Prism software V.6.0 was used for statistical analyses.
Since the majority of our data did not pass the D’Agostino and
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Pearson omnibus normality test, two groups were compared by
the non-parametrical Mann-Whitney U test after testing the
global null hypothesis by the Kruskal-Wallis test. Local p values
were adjusted by the global p value to preserve the family-wise
error rate.28 p Values ≤0.05 were considered statistically
signiﬁcant.
RESULTS
Primary outcome
To evaluate whether VEGF121 modiﬁed ﬁbrin heals and pre-
vents ischaemic ulcerations, we locally treated early inﬂamma-
tory comb lesions (C++), and late comb and neck skin ulcers
(C+++, N+++) of UCD-206 chickens. After 1 week of treat-
ment the clinical outcome was assessed (ﬁgure 1). Two animals
treated with VEGF121-ﬁbrin had lost the dressing and therefore
were excluded from the study, that is, one with C++ lesion and
one with N+++ lesion. From the comb lesions treated with
VEGF121-ﬁbrin in the early inﬂammatory C++ stage, six
(66.7%) showed improvement, one (11.1%) deterioration and
two (22.2%) halt of disease progression. Fibrin treated C++
lesions improved in two chickens (20.0%), worsened in seven
(70.0%) and showed no change in one animal. All 10 untreated
C++ lesions deteriorated. Nine comb lesions (90.0%) treated
with VEGF121-ﬁbrin in the late ischaemic C+++ stage showed
improvement, one lesion deteriorated. In the ﬁbrin treated
group only one C+++ lesion improved slightly, eight (80.0%)
worsened and one (10.0%) was unchanged. In the untreated
C+++ group there was one (10.0%) spontaneous healing, one
without change and eight (80.0%) with clear deterioration.
Ulcerations of neck skin were clearly improved in eight animals
(80.0%) after VEGF121-ﬁbrin treatment, and showed no change
in two chickens. Fibrin treatment improved only two N+++
lesions (18.2%), two (18.2%) were unaltered and seven (63.6%)
progressed further. All 10 untreated lesions were strongly dete-
riorated. There was 100% agreement between the three blinded
independent investigators in the semiquantitative clinical assess-
ment in 60% of the cases; in 38% of the cases, two of the inves-
tigators showed 100% concordance, one differed by one degree
up or down. The three investigators disagreed only in two cases
on the severity of deterioration.
Figure 1 Clinical outcome 7 days after treatment. Representative examples of comb and neck lesions photographed before (A–C, H–J, O–Q), and
after 1 week of treatment (D–F, K–M, R–T). Lesions at beginning of therapy: ++, erythema and oedema; +++, beginning necrosis. Results of clinical
assessment by three blinded examiners of comb ++ (G), comb +++ (N), and neck +++ (U). Degree of change: 0=no change, +1=improvement,
+2=strong improvement, −1=deterioration, −2=strong deterioration. p Values have been calculated using the Mann-Whitney U test adjusted by the
Kruskal-Wallis test. Each dot represents a single lesion. Horizontal lines indicate the median. VEGF, vascular endothelial growth factor.
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Effect of VEGF121-ﬁbrin on angiogenesis
To assess whether VEGF121-ﬁbrin induces the growth of mature
blood vessels, we quantitatively analysed frozen tissue sections
stained by IIF with EC speciﬁc anti-vWF antibodies and
anti-αSMA antibodies as a marker for mural cells. One of the
ﬁbrin treated C++ samples was lost due to accidental defrost-
ing, and thus not included in the studies on angiogenesis.
Microvascular density was signiﬁcantly increased in
VEGF121-ﬁbrin treated early comb lesions, late comb lesions,
and neck skin ulcers compared with ﬁbrin treated and untreated
lesions (ﬁgure 2A, D, G). The difference was also signiﬁcant
between VEGF121-ﬁbrin and ﬁbrin treated samples. Fibrin itself
also increased the number of ECs signiﬁcantly compared with
untreated lesions. PC numbers were signiﬁcantly elevated in all
VEGF121-ﬁbrin treated groups compared with untreated con-
trols (ﬁgure 2B, E, H). Fibrin alone increased the number of
PCs as well, but to a lesser extent. In late comb and neck ulcers,
however, the effect of VEGF121-ﬁbrin was signiﬁcantly higher
than of ﬁbrin only. Signiﬁcantly more vascular SMCs (vSMCs)
were found in all VEGF121-ﬁbrin treated lesions, and ﬁbrin only
groups compared with untreated controls (ﬁgure 2C, F, I).
Increase of mural cell numbers after treatment with
VEGF121-ﬁbrin was conﬁrmed by desmin staining (see online
supplementary ﬁgure S1).
To study the regulatory effects of VEGF121-ﬁbrin on the
expression of VEGF receptors VEGFR-1 and VEGFR-2, we
determined the numbers of VEGFR-1/vWF double stained cells
and the numbers of VEGFR-2/vWF double stained cells using
TissueQuest, and calculated ﬁrst the ratio of VEGFR-1 to
VEGFR-2 expressing ECs. We then calculated the change of this
ratio (x) in relation to healthy controls with the equation
x ¼ ðy 100=xhealthyÞ  100; where y is the VEGFR-1:
VEGFR-2 ratio of individual samples. Whereas in the majority
of untreated lesions the VEGFR-1:VEGFR-2 ratio was increased
in relation to healthy controls, the change of the VEGFR-1:
VEGFR-2 ratio was signiﬁcantly lower after VEGF121-ﬁbrin
treatment compared with untreated combs, and ﬁbrin treated
comb lesions (ﬁgure 3A, B). Neck skin lesions also showed a
clear change of VEGFR-1:VEGFR-2 ratio after treatment with
VEGF121-ﬁbrin compared with ﬁbrin and untreated controls.
However the signiﬁcance between groups was lost after
Kruskal-Wallis adjustment (VEGF121-ﬁbrin: median=−75.2
(IQR=−90.9 to −53.0), ﬁbrin: −66.5 (−83.1 to 179.1); ﬁgure
3C–F). The reduction of the VEGFR-1:VEGFR-2 ratio was in
part due to increased VEGFR-2 expression. To conﬁrm this
ﬁnding we also analysed the expression of TAL-1/SCL, a positive
regulator of VEGFR-2 (ﬁgure 4). Compared with untreated con-
trols VEGF121-ﬁbrin increased the number of TAL-1 expressing
ECs in early comb lesions, late comb lesions and neck ulcers. In
the latter, the difference between VEGF121-ﬁbrin and ﬁbrin
treatment was also statistically signiﬁcant, whereas in comb
lesions TAL-1 expressing ECs were elevated by ﬁbrin compared
with untreated controls.
Furthermore, we wanted to know if the exogenous
VEGF121-ﬁbrin has an inﬂuence on VEGF production by ECs.
The number of VEGF expressing ECs was increased after
VEGF121-ﬁbrin treatment of comb and neck ulcers compared
with ﬁbrin and untreated controls. These differences were
clearly signiﬁcant in C+++, but not signiﬁcant after
Kruskal-Wallis adjustment in neck lesions (VEGF121-ﬁbrin:
235.4 (72.9–636.7), ﬁbrin: 74.1 (36.0–316.8), untreated
control: 116.4 (54.9–146.7); ﬁgure 5).
Figure 2 Effects of VEGF-therapy on angiogenesis. (A–I) display quantitative analyses of endothelial cells (ECs), pericytes (PCs) and vascular
smooth muscle cells (vSMCs) after 1 week of treatment of early inﬂammatory comb lesions (C++; A–C), of comb ulcers (C+++; D–F), and neck
ulcers (N+++, G–I). p Values have been calculated using the Mann-Whitney U test adjusted by the Kruskal-Wallis test. Each dot represents a single
lesion. Horizontal bars indicate median values. Representative false colour immunoﬂuorescence pictures of neck skin ulcers treated locally with
VEGF121-ﬁbrin ( J), ﬁbrin (K) or left untreated (L) depicting vWF staining, α smooth muscle actin (αSMA) staining, vWF/αSMA overlays and vWF/
αSMA/DAPI overlays. Original magniﬁcation ×200. VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
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DISCUSSION
The novelty and attractiveness of the current approach lies in
the bioavailability of VEGF on cellular demand. This speciﬁcally
addresses an unmet need in SSc where we have the situation of
insufﬁciently increased VEGF levels. Moreover, some of the
overexpressed VEGF might be antiangiogenic.29 Both aspects
are addressed by the ﬁbrin-bound VEGF gel: it provides locally
in the wound bed sufﬁcient amounts of VEGF and at the same
time, the release of VEGF is on demand of the cells and the
local release is stopped after it is no longer required. Our study
in UCD-206 chickens convincingly showed the clinical efﬁcacy
of the topical VEGF121-ﬁbrin therapy. In most cases of early
treatment, that is, in combs with oedema but no ulceration,
VEGF121-ﬁbrin prevented the development of ischaemic ulcers.
In total, only two animals (6.9%) did not respond to
VEGF121-ﬁbrin at all, and showed the same disease progression
as untreated animals. Spontaneous healing was observed in
only one untreated chicken with comb ulcer. Fibrin gel alone
had a moderate improving effect on ﬁve lesions (16.1%).
Overall, 79.3% of the VEGF121-ﬁbrin treated lesions showed
clear clinical improvement, whereas 71.0% of ﬁbrin treated con-
trols and 93.1% of untreated lesions had deteriorated. It should
be noted here that, although closed bred, UCD-206 chickens
are not an inbred line, and thus, like humans do not react
uniformly.
VEGF121-ﬁbrin had effectively promoted angiogenesis, leading
to increased microvascular density. This is also reﬂected by sig-
niﬁcantly more ECs in comb and neck lesions treated with
VEGF121-ﬁbrin compared with ﬁbrin or untreated controls.
Nascent blood vessels initially consist only of ECs and have to be
stabilised by mural cells.30 Mural cells of capillaries are referred
to as PCs, those of arteries, arterioles, and veins as vSMCs. They
Figure 3 Endothelial expression of VEGFR-1 and VEGFR-2. Changes in the ratio of VEGFR-1 to VEGFR-2 expressing endothelial cells after 1 week
of treatment of early inﬂammatory comb lesions (C++; A), of comb ulcers (C+++; B) and neck ulcers (N+++; C). Data expressed as change of the
VEGFR-1:VEGFR-2 ratio in % from healthy control chickens, where the mean value of healthy chickens was deﬁned as 0% change. Note that some
deteriorated lesions showed no VEGFR-1 and VEGFR-2 expression, so that it was not possible to calculate the VEGFR-1:VEGFR-2 ratio. p Values have
been calculated using the Mann-Whitney U test adjusted by the Kruskal-Wallis test. Each dot represents a single lesion. Horizontal bars indicate
median values. Representative false colour immunoﬂuorescence pictures of neck skin ulcers treated locally with VEGF121-ﬁbrin (D), ﬁbrin (E) or left
untreated (F) showing single channel and overlays; upper panels: VEGFR-1, lower panels: VEGFR-2. Original magniﬁcation ×200. VEGF, vascular
endothelial growth factor; vWF, von Willebrand factor.
Allipour Birgani S, et al. Ann Rheum Dis 2015;0:1–8. doi:10.1136/annrheumdis-2015-207548 5
Basic and translational research
group.bmj.com on November 20, 2015 - Published by http://ard.bmj.com/Downloaded from 
both express αSMA, but can be distinguished by their localisa-
tion.31 We have set the parameters of the image analysis software
TissueQuest in order to discriminate vSMCs, which are separated
from ECs by the basement membrane or in larger arteries by the
intima, and PCs, which share the basement membrane with the
ECs and are in direct contact with these. Whereas only few mural
cells were detected in untreated lesions, all the blood vessels of
VEGF121-ﬁbrin treated ulcers looked ensheathed by PCs or
vSMCs suggesting the formation of mature, stable vessels.
Desmin staining corroborated these ﬁndings.
The ﬁbrin glue Tisseel, which we used to form the ﬁbrin
matrix, stimulated angiogenesis itself. Fibrin is the major com-
ponent of blood clots, and serves as a provisional matrix during
wound healing. Fibrin supports every stage of angiogenesis, that
is, migration of ECs, tube formation and vessel maturation. In a
rabbit model of hind limb ischaemia it has been found to
promote angiogenesis even without the addition of any other
proangiogenic factor.32 Thrombin, another component of
Tisseel, as well as FXIII are also known to mediate angiogen-
esis.33 34 FXIII was used to covalently bind VEGF121 to ﬁbrin,
but was also added to the placebo control. In vitro and in vivo
studies have revealed that FXIII promotes migration and prolif-
eration of ECs, inhibits apoptosis, and downregulates the antian-
giogenic factor TSP-1 via VEGFR-2 activation.34 35 Thus, all
three components might contribute to the therapeutic effect of
VEGF121-ﬁbrin. However, VEGF121-ﬁbrin showed signiﬁcantly
greater efﬁcacy than the ﬁbrin sealant with FXIII, especially in
the treatment of late ischaemic ulcers of comb and neck skin.
Therapy with VEGF121-ﬁbrin affected the expression of
VEGFR-1 and VEGFR-2. Most of the VEGF signalling described
to date is primarily mediated via VEGFR-2, that is, survival,
migration, proliferation and vascular tube formation.36 In devel-
opmental angiogenesis VEGFR-1 acts as decoy receptor nega-
tively regulating VEGFR-2 signalling.37 The role of VEGFR-1 in
postnatal angiogenesis is less clear, and seems to be context
dependent. However, several lines of evidence suggest an
Figure 4 Endothelial expression of the VEGFR-2 regulator TAL-1. TAL-1 expression in endothelial cells (ECs) was quantiﬁed on immunoﬂuorescence
TAL-1/vWF double stained frozen tissue sections 1 week after treatment of early inﬂammatory comb lesions (C++; A), of comb ulcers (C+++; B) and
neck ulcers (N+++; C). p Values have been calculated using the Mann-Whitney U test adjusted by the Kruskal-Wallis test. Each dot represents a
single lesion. Horizontal bars indicate median values. Representative false colour immunoﬂuorescence pictures of neck skin ulcers treated locally
with VEGF121-ﬁbrin (D), ﬁbrin (E) or left untreated (F) showing single channel and overlays. Original magniﬁcation ×200. VEGF, vascular endothelial
growth factor; vWF, von Willebrand factor.
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association of increased VEGFR-1 expression with impaired
angiogenesis. VEGFR-1 levels are increased in chronic non-
healing wounds, whereas in normal healing wounds granulation
tissue formation is positively correlated with a decline in
VEGFR-1.38 Elevated VEGFR-1 levels have been reported to
promote endothelial injury in children with lupus nephritis,39
and to inhibit endothelial repair in PR3-ANCA associated vascu-
litis.40 Upregulation of VEGFR-1 and VEGFR-2 was demon-
strated in SSc skin.14 41 However, some of these semiquantitative
results are contradictory. Whereas one study described a more
pronounced VEGFR-2 expression, the other found more
VEGFR-1. In bone marrow, diminished angiogenesis was asso-
ciated with decreased VEGFR-2 expression and high VEGF
levels.42 It is possible that differences between patients and the
small sample numbers account for diverging results, but in
general, they indicate activation of the VEGF/VEGFR system and
imbalanced expression of VEGF and its receptors. VEGF action
is regulated by the availability of its receptors. Therefore, it
seems very likely that the ratio of VEGFR-1:VEGFR-2 rather
than the absolute numbers determines the angiogenic status in
the tissue. In lesional UCD-206 comb and neck skin the balance
between the two receptors is shifted towards VEGFR-1. On
exposure to VEGF121-ﬁbrin the VEGFR-1:VEGFR-2 ratio was
normalised due to differential regulation of VEGFR-1 and
VEGFR-2 expression with a relative increase in endothelial
VEGFR-2. Upregulation of VEGFR-2 expression concurred with
increased TAL-1 expression. TAL-1 is a basic-helix-loop-helix
transcription factor known to be essential for haematopoietic
development. It is also required during vascular development
and angiogenesis, and has been identiﬁed as a positive regulator
of VEGFR-2.43 Moreover, endogenous VEGF expression was
induced by modiﬁed VEGF121 in comb and neck skin ulcers. As
autocrine VEGF signalling is required for endothelial survival,44
this might indicate the induction of lasting vascularisation.
All these results support the notion that cell-demanded
release of ﬁbrin-bound VEGF is capable of translating a
Figure 5 Endogenous VEGF expression in endothelial cells (ECs). Endogenous VEGF expression by ECs was quantiﬁed on immunoﬂuorescence
VEGF/vWF double stained frozen tissue sections after 1 week of treatment of early inﬂammatory comb lesions (C++; A), of comb ulcers (C+++; B)
and neck ulcers (N+++; C). p Values have been calculated using the Mann-Whitney U test adjusted by the Kruskal-Wallis test. Each dot represents a
single lesion. Horizontal bars indicate median values. Representative false colour immunoﬂuorescence pictures of neck skin ulcers treated locally
with VEGF121-ﬁbrin (D), ﬁbrin (E) or left untreated (F) showing single channel and overlays. Original magniﬁcation ×200. VEGF, vascular endothelial
growth factor; vWF, von Willebrand factor.
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supraphysiological dose into a physiological tiny dose, of sus-
taining this dose long enough to permit vessels to mature into
stable vessels, and of stopping it if no longer needed. Otherwise
chronic exposure would have harmful effects again.
Furthermore, this study indicates that even a singular local
administration of VEGF121-ﬁbrin can achieve sufﬁcient revascu-
larisation to improve existing ulcers or prevent the development
of ulcers in our SSc animal model. For clinical applications,
long-term effects and potential side effects of VEGF121 need
particular attention.
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